Login to Your Account


Cellectis stock surges 50 percent on Pfizer chimeric antigen receptor T-cell cancer deal

By Cormac Sheridan
Staff Writer

Thursday, June 19, 2014
Shares in Cellectis SA surged more than 50 percent during trading in Paris Wednesday after Pfizer Inc. unveiled a strategic collaboration in cancer based on the French firm's allogeneic chimeric antigen receptor T-cell (CAR T-cell) platform, which will involve an initial outlay of about $112 million, as well as research funding, milestones that could reach as much as $2.775 billion in total, and tiered royalties on any products that reach the market.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription